CYTR - CytRx Corporation
| Previous Close | 0.3310 |
| Open | 0.3300 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 1000 |
| Day's Range | 0.3300 - 0.3600 |
| 52 Week Range | 0.2600 - 1.2900 |
| Volume | 36,730 |
| Avg. Volume | 180,928 |
| Market Cap | 11.1M |
| Beta (3Y Monthly) | 2.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3100 |
| Earnings Date | Nov 6, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.50 |
- MarketWatch•4 days ago
Nasdaq delists shares of FTD, Insys, others
The Nasdaq Stock Market said late Friday it was delisting four stocks that had traded on its exchange. Nasdaq said that it delisted shares of FTD Cos. , Kaixin Auto Holdings , CytRx Corp. , and Insys Therapeutics Inc. . The exchange said that trading in FTD shares was suspended on June 13, while shares of Kaixin were suspended June 11, CytRx shares were suspended June 4, and Insys shares were suspended June 19.
- PR Newswire•6 days ago
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type C
LOS ANGELES, June 19, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing principally in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has updated the anticipated timing for submission of its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval for arimoclomol in Niemann-Pick disease Type C (NPC). Based on advice received from the EMA's Scientific Advice Working Group, Orphazyme expects to submit the arimoclomol MAA in the first half of 2020.
- PR Newswire•25 days ago
CytRx Corporation to Commence Trading on OTCQB Venture Market
LOS ANGELES, May 31, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will commence trading on the OTCQB Venture Market as of Tuesday, June 4, 2019, under the same ticker symbol "CYTR". Investors can find current financial disclosure and real-time Level 2 quotes for the Company on www.otcmarkets.com/stock/CYTR/quote.
- Associated Press•last month
CytRx: 1Q Earnings Snapshot
The Los Angeles-based company said it had a loss of 4 cents per share. Losses, adjusted to account for discontinued operations, were 5 cents per share. The company's shares closed at 52 cents. A year ago, ...
- PR Newswire•last month
CytRx Corporation Reports First Quarter 2019 Financial Results
Out-licensed Assets Aldoxorubicin and Arimoclomol Rapidly Advancing into Multiple Indications of High Unmet Need CytRx Stands to Receive Significant Future Milestone Payments and Royalties from Licensing ...
- PR Newswire•2 months ago
CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer
"We are continually impressed with the progress that our partner and licensee NantCell has made with advancing aldoxorubicin in high unmet need oncology indications," said Eric Curtis, CytRx's President and Chief Operating Officer.
- PR Newswire•2 months ago
CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S
CytRx Eligible to Receive up to $120 Million in Future Milestones, Plus Royalties, From Arimoclomol Licensing Agreement LOS ANGELES , May 2, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical ...
- PR Newswire•2 months ago
CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S
CytRx Eligible to Receive up to $120 Million in Future Milestones, Plus Royalties, From Arimoclomol Licensing Agreement LOS ANGELES , April 29, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a ...
- PR Newswire•3 months ago
CytRx Corporation Reports 2018 Financial Results
LADR™ Assets Well Aligned with Current Oncology Trends, Including Need for Improved Drugs and Potential for Combination with Immunotherapy Out-licensed Assets Aldoxorubicin and Arimoclomol with Strategic ...
- PR Newswire•3 months ago
CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems
LOS ANGELES, March 12, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology treatment and diagnostics, and its private, wholly-owned subsidiary Centurion BioPharma Corporation, today announced the publication of peer reviewed, scientific research for its Albumin Companion Diagnostic (ACDx). The article, titled "Development of a Novel Imaging Agent for Determining Albumin Uptake in Solid Tumors," has been published online in Nuclear Medicine and Molecular Imaging. The abstract may be found and the full article purchased online at https://doi.org/10.1007/s13139-019-00587-w.
- PR Newswire•4 months ago
CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the Tumor
LOS ANGELES, Feb. 13, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, and its private, wholly-owned subsidiary Centurion BioPharma Corporation, today announced the publication of peer reviewed, scientific research for LADR-7 (AE-Keto-Sulf07), one of its lead LADR™ (Linker Activated Drug Release) candidates. The article, entitled "Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound" to be published in the Journal of Controlled Release, a leading journal for drug delivery on February 28, 2019. The abstract may be found and full article purchased online at https://www.sciencedirect.com/journal/journal-of-controlled-release/vol/296.
- PR Newswire•4 months ago
CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy
LOS ANGELES, Feb. 11, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted comments from an OncLive® article dated February 1, 2019 that an estimated majority of oncology patients do not have targetable genetic mutations that would make them eligible for targeted treatment.
- PR Newswire•5 months ago
CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S
LOS ANGELES, Feb. 6, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, highlighted positive Phase 2/3 clinical trial data from arimoclomol licensee Orphazyme A/S (ORPHA.CO). Orphazyme is currently developing arimoclomol in four different indications, including amyotrophic lateral sclerosis (ALS), Niemann-Pick disease Type C (NPC), Gaucher disease and sporadic Inclusion Body Myositis (sIBM).
- PR Newswire•5 months ago
CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial
LOS ANGELES, Jan. 14, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a Phase 1b/2 clinical trial for patients with relapsed or refractory colorectal cancer (CRC) who have been previously treated with standard of care (SOC) therapy. This is the fourth trial conducted by NantCell which will investigate high-affinity natural killer (haNK) cell therapy in combination with anti-cancer agents, including aldoxorubicin, in certain high unmet need cancer indications.
- PR Newswire•6 months ago
CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates and Accompanying Companion Diagnostic
LOS ANGELES, Dec. 21, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its private, wholly-owned subsidiary Centurion BioPharma Corporation (the Company) has concluded the pre-clinical phase of its development for its albumin binding ultra high potency LADR™ (Linker Activated Drug Release) drug candidates, LADR-7, LADR-8, LADR-9 and LADR-10, and for its unique albumin companion diagnostic (ACDx). As a result of completing this work, operations taking place at the pre-clinical laboratory located in Freiburg, Germany will no longer be needed. The LADR™ platform combines Centurion's proprietary linker chemistry with albumin biology to create anti-cancer molecules that the Company believes will deliver highly potent agents directly to the tumor, while avoiding unacceptable systemic toxicity. The pre-clinical laboratory synthesized and evaluated over 75 rationally-designed drug conjugates across two distinct classes of compounds, the auristatins and maytansinoids.
- PR Newswire•7 months ago
CytRx Corporation to Present at the 11th Annual LD Micro Main Event
CytRx's wholly owned subsidiary, Centurion BioPharma Corporation, is focused on the development of personalized medicine that will transform solid tumor treatment. This transformational strategy combines a portfolio of novel, anti-cancer drug candidates that employ LADR™ (Linker Activated Drug Release) technology, a discovery engine designed to leverage Centurion's expertise in albumin biology and linker technology for the development of a new class of breakthrough anti-cancer therapies with a unique albumin companion diagnostic (ACDx) that can help identify patients who are most likely to benefit from treatment with the LADR™-derived therapies. This technology allows for the delivery of higher doses of drug directly to the tumor, while avoiding much of the off-target toxicity observed with the parent molecules. Centurion BioPharma Corporation's website is www.centurionbiopharma.com.
- GlobeNewswire•7 months ago
Report: Exploring Fundamental Drivers Behind Graphic Packaging Holding, QEP Resources, Inogen, CytRx, Voyager Therapeutics, and Daily Journal Corp. (S.C.) — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•7 months ago
Edited Transcript of CYTR earnings conference call or presentation 2-Nov-18 3:00pm GMT
Q3 2018 CytRx Corp Earnings Call
- Zacks•7 months ago
Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems
Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems
- Zacks•7 months ago
Bet on Rising P/E Investing With These 5 Top-Ranked Stocks
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
- PR Newswire•8 months ago
CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
Aldoxorubicin Is Part of the NANT Cancer Vaccine Combinations Which Include Immunotherapy and Cell-based Therapy Early Safely Data Are Encouraging and There Are Emerging Positive Signals of Clinical Activity ...
- Associated Press•8 months ago
CytRx: 3Q Earnings Snapshot
On a per-share basis, the Los Angeles-based company said it had a loss of 10 cents. The cancer drug developer posted revenue of $250,000 in the period. The company's shares closed at 75 cents. A year ago, ...
- PR Newswire•8 months ago
CytRx Corporation Reports Third Quarter 2018 Financial Results
Quarter Marked by Centurion's Filing of a Provisional Patent for Breakthrough Personalized Medicine Companion Diagnostic to Accompany LADR Assets Improved Finances and Capital Structure Through Expiration ...
- PR Newswire•8 months ago
Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline
LOS ANGELES, Oct. 31, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that key emerging cancer treatment trends by Big Pharma, including combining immunotherapy with effective chemotherapy regimens, are resulting in significant advancements for the treatment of patients with high unmet medical need types of cancer. CytRx, along with its wholly owned subsidiary Centurion Biopharma, believe these trends strengthen and enhance the value proposition for their rationally designed albumin binding ultra-high potency anti-cancer agents.
- PR Newswire•8 months ago
CytRx to Hold Third Quarter 2018 Financial Results Conference Call and Webcast on Friday, November 2, 2018
LOS ANGELES , Oct. 29, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will report financial ...
